The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Novel targeted and anti-inflammatory strategies advance MPN treatment landscape
Lucia Masarova, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses emerging therapeutic strategies and novel mechanisms in myeloproliferative neoplasms (MPNs), including myelofibrosis. Dr Masarova highlights ongoing research into targeted therapies, monoclonal antibodies, and anti-inflammatory approaches aimed at disease modification, while emphasizing the future role of combination strategies and personalized treatment selection in MPN care. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
